The NASH curse strikes again. Pfizer dumps early-stage asset for liver condition

Another NASH drug bites the dust. This time it’s Pfizer’s early-stage asset danuglipron, which the drugmaker has dumped for the liver condition.

The GLP1 agonist, also known as PF-06882961, will no longer be pushed forward as a potential treatment for non-alcoholic steatohepatitis, according to Pfizer’s pipeline website and second quarter earnings report. The 22-person phase 1 trial wrapped up in January, according to ClinicalTrials.gov, but Pfizer has yet to post the results. Trials for the GLP1 agonist to treat obesity and diabetes appear to be ongoing, according to the earnings documents.